Волрустомиг
VolrustomigМНН
Rec. INN (наименование, зарегистрированное ВОЗ)
USAN (наименование, принятое к употреблению в США)
CAS
2407760-40-9
Химическое название
immunoglobulin G1-kappa/kappa-lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)] and anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated protein 4, CTLA-4, CD152)], humanized and Homo sapiens monoclonal antibody, bispecific, bivalent;
gamma1 heavy chain anti-PDCD1 humanized (1-452) [VH anti-PDCD1 humanized (Homo sapiens IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01, L123>T (117) (93.3%), CDR-IMGT [8.8.15] (26-33.51-58.97-111) (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), P116>S (336) (236-345), CH3 Y5>C (354), E12 (361), M14 (363), T22>S (371), L24 >A (373), Y86>V (412) (346-450), CHS (451-452)) (123-452)], (225-219')-disulfide with kappa light chain anti- PDCD1 humanized (1'-219') [V-KAPPA (Homo sapiens IGKV3-11*01 (81.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%) A45.1 (158), V101 (196) (113'-219') (113'-219')];
gamma1 heavy chain anti-CTLA4 Homo sapiens (1''-455'') [VH anti-CTLA4 (Homo sapiens IGHV3-33*01 (100%) -(IGHD) -IGHJ6*01 (100%)) CDR-IMGT [8.8.18] (26-33.51-58.97-114) (1''-125'') -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v32 CH3 W32 (knob) (CH1 F5>C (134), R120 (222) (126''-223''), hinge 1-15, C5>V (228) (224''-238''), CH2 L1.3>F (242), L1.2>E (243), P116>S (339) (239''-348''), CH3 S10>C (362), E12 (364), M14 (366), T22>W (374) (349''-453''), CHS (454-455)) (126''-455'')], (134''-122''')-disulfide with kappa-lambda light chain anti-CTLA4 Homo sapiens (1'''-213''') [V-KAPPA anti-CTLA4 (Homo sapiens IGKV1-39*01 (96.8%) -IGKJ3*01, D125>E (91.7%), CDR-IMGT [6.3.7] (27-32.50-52.89-95) (1'''-107''') -Homo sapiens IGLC2*01, S10>C (122), C126>V (212) (98.1%) (108'''-213''')];
heterodimer (231-234'':234-237'':354-362'')-trisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
gamma1 heavy chain anti-PDCD1 humanized (1-452) [VH anti-PDCD1 humanized (Homo sapiens IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01, L123>T (117) (93.3%), CDR-IMGT [8.8.15] (26-33.51-58.97-111) (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), P116>S (336) (236-345), CH3 Y5>C (354), E12 (361), M14 (363), T22>S (371), L24 >A (373), Y86>V (412) (346-450), CHS (451-452)) (123-452)], (225-219')-disulfide with kappa light chain anti- PDCD1 humanized (1'-219') [V-KAPPA (Homo sapiens IGKV3-11*01 (81.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -Homo sapiens IGKC*01 (100%) A45.1 (158), V101 (196) (113'-219') (113'-219')];
gamma1 heavy chain anti-CTLA4 Homo sapiens (1''-455'') [VH anti-CTLA4 (Homo sapiens IGHV3-33*01 (100%) -(IGHD) -IGHJ6*01 (100%)) CDR-IMGT [8.8.18] (26-33.51-58.97-114) (1''-125'') -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v32 CH3 W32 (knob) (CH1 F5>C (134), R120 (222) (126''-223''), hinge 1-15, C5>V (228) (224''-238''), CH2 L1.3>F (242), L1.2>E (243), P116>S (339) (239''-348''), CH3 S10>C (362), E12 (364), M14 (366), T22>W (374) (349''-453''), CHS (454-455)) (126''-455'')], (134''-122''')-disulfide with kappa-lambda light chain anti-CTLA4 Homo sapiens (1'''-213''') [V-KAPPA anti-CTLA4 (Homo sapiens IGKV1-39*01 (96.8%) -IGKJ3*01, D125>E (91.7%), CDR-IMGT [6.3.7] (27-32.50-52.89-95) (1'''-107''') -Homo sapiens IGLC2*01, S10>C (122), C126>V (212) (98.1%) (108'''-213''')];
heterodimer (231-234'':234-237'':354-362'')-trisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
Структура
Иностранные названия
- Volrustomigum (латинское)
- Volrustomig (английское)
- Volrustomig (немецкое)
- Volrustomig (французское)
- Volrustomig (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Волрустомиг: